Dr. Jufeng Wang Appointed as Sr. VP and TFM of the Safety Assessment Facility at Pharmaron

Pharmaron today announced the appointment of Dr. Jufeng Wang, as Senior Vice President and Test Facility Manager (TFM) of its safety assessment facility in Beijing. Dr. Wang brings over 20 years of experience and skills in the drug safety assessment area, not only in science and technologies, also in leading a GLP compliant safety assessment facility.

Prior to joining Pharmaron, Dr. Wang was Director of National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, affiliated with Chinese FDA. In this capacity, Dr. Wang was involved in all aspects of safety assessment activities for novel drugs, including the review and revision of national drug technical guidelines and GLP guideline revision and establishing and validating new safety assays using cutting-edge technologies. In addition, Dr. Wang has abundant experience in the US pharmaceutical industry in the fields of toxicology and safety pharmacology.

“We are pleased to have Dr. Wang join Pharmaron,” said Dr. Boliang Lou, Chairman & CEO. “Dr. Wang’s international experiences in both China and the US in the GLP regulatory environment will help Pharmaron further strengthen its R&D service leadership, allowing us to provide better services to our partners.”

About Pharmaron

Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism to chemical and pharmaceutical development.  By integrating the platforms, Pharmaron offers integrated services for hit and lead identification, lead optimization, PCC selection, and IND and NDA enabling. With over 4,000 employees and operations in China, the U.S. and the UK, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit www.pharmaron.com.

康龙化成任命汪巨峰博士为高级副总裁并担任其药物安全性评价机构负责人

康龙化成今天宣布任命汪巨峰博士为公司高级副总裁并担任其药物安全性评价机构负责人。汪博士从事药物安全性评价工作超过20年,在药物安全性评价领域及机构的GLP法规遵循管理方面积累了非常丰富的经验。

加入康龙化成前,汪博士曾任CFDA中国食品药品检定研究院食品药品安全评价研究所所长。在任期间,汪博士曾领导并全面参与了众多新型药物的安全性评价工作、审查并修订了国家药物研发技术指南、修订GLP准则、利用尖端生物技术建立并验证了众多新的安评方法。此外,汪博士在美国制药行业的毒理学和安全药理学领域也拥有丰富的经验。

“很高兴汪巨峰博士加入康龙化成,”康龙化成董事长兼CEO楼柏良博士表示,“汪博士拥有在GLP法规环境下工作的国际经验,他的加入将进一步巩固康龙化成在药物研发服务行业的领先地位,为我们的合作伙伴提供更优质的服务。”

关于康龙化成

康龙化成新药技术有限公司(非上市企业),成立于2003年,是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务,帮助伙伴们成功开发新药,降低新药研发成本,提高新药研发效率”。经过多年发展,康龙化成打造了全方位的临床前药物研发一体化平台,贯穿合成与药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、放射标记代谢、工艺研发、GMP生产及制剂研发服务等各个领域,提供包括苗头化合物探索与靶标验证、先导化合物优化、临床前候选药物筛选、新药临床研究申请和新药申报等一体化研发服务。康龙化成在中国、美国、英国均有运营实体,拥有4000多名员工,一流的人才队伍,高质量的研发服务,获得了业界的广泛认可,与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。详情请访问公司网站:

www.pharmaron.com